What Is the CADTH Reimbursement Recommendation for Lumakras?: CADTH recommends that public drug plans should not reimburse Lumakras for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homologue (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) who have received at least 1 prior systemic therapy.

Why Did CADTH Make This Recommendation?:

1. The clinical evidence reviewed by CADTH was insufficient to conclude that treatment with Lumakras results in a clinically meaningful delay in disease progression compared with docetaxel. It was impossible to assess whether treatment with Lumakras would prolong survival relative to docetaxel.

2. Patients identified the need for more effective treatments that delay disease progression, prolong survival, control disease symptoms, improve quality of life, reduce side effects, and offer an oral route of administration. While Lumakras offers an oral route of administration, it is not clear whether Lumakras meets the other needs identified by patients.

What Is KRAS G12C-Mutated NSCLC?: NSCLC occurs when healthy cells in the lung become cancerous and is considered metastatic when cancer cells have spread to other parts of the body. Approximately 30,000 new cases of NSCLC are diagnosed each year in Canada. Approximately 7.9 per 100,000 patients with NSCLC have KRAS G12C mutations, which can lead to poor disease outcomes.

Unmet Needs in KRAS G12C-Mutated NSCLC: There are limited treatment options for patients with KRAS G12C-mutated NSCLC who have progressed on standard therapy. Effective treatments that can be administered orally, prolong survival, improve quality of life, and have fewer side effects are needed.

How Much Does Lumakras Cost?: Treatment with Lumakras is expected to cost approximately $10,806 per 28 days.